Key facts about Reyvow
What is Reyvow?
Reyvow is the brand name for lasmiditan and is available as an oral tablet.
What dosages is Reyvow available in?
Reyvow is available as a 50 mg and 100 mg oral tablet.
What is Reyvow used for?
Reyvow is a serotonin agonist and is used to treat migraines with or without aura in adults.
How does Reyvow work?
Reyvow is a serotonin agonist, which means it works on serotonin receptors in your brain and activates them (wakes them up). It’s not exactly known how Reyvow helps with migraines, but when serotonin receptors are activated, they block pain signals.
How do I take Reyvow?
Reyvow is typically dosed as 50 mg, 100 mg, or 200 mg by mouth once as needed when you have a migraine attack. Don’t take more than 1 dose in a 24-hour period.
Is it safe for me to take Reyvow?
Reyvow is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.
Reyvow Common Side Effects
Common side effects of Reyvow:
- Dizziness
- Numbness or tingling
- Sleepiness
- Tiredness
Reyvow Serious Side Effects
Serious side effects are rare with Reyvow. Contact your healthcare provider immediately if you experience any of the following.
- Serotonin syndrome: fast heart rate, sweating, muscle stiffness or spasms, fever, confusion
- Serious allergic reactions: swelling of your face, lips, tongue, or throat, difficulty breathing, hives
Effects of other drugs, drug classes and over-the-counter products on Reyvow
The following medications may interact with Reyvow:
- Reyvow may further lower heart rate when administered with heart rate lowering drugs
Who makes Reyvow?
Eli Lilly and Company
Is Reyvow safe in pregnancy?
It is not known if Reyvow can harm an
unborn baby. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Notify your healthcare provider if you become pregnant during treatment or plan to become pregnant.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Reyvow during
pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves
in the registry by calling 1-833-464-4724. To learn more please call or visit Migraine pregnancy registry
